Edwards Lifesciences Corp. reported better than expected second quarter results, driven by continued growth of its largest segment. Shares in Edwards climbed 5% in after-hours trading to $88 apiece following the July 23 earnings announcement. TAVR Q2 Sales Grow 11.3% to $1.26BAt the center of Edwards’ strong quarter was its transcatheter aortic valve (TAVR) business, which grew 11% in sales to $1.26 billion. In addition to its full-year outlook, Edwards increased sales growth guidance for TAVR to 8%-9% from 7%-9%. CMS Proposes Update to Medicare Coverage for TAVRA pending update to the Centers for Medicare & Medicaid Services’ (CMS) national coverage determination could expand access to Edwards’ TAVR technologies.